A5069536978- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Cancer-related gene regulation
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Dental Radiography and Imaging
- Microscopic Colitis
- Galectins and Cancer Biology
- Colorectal Cancer Surgical Treatments
- Whipple's Disease and Interleukins
- Ovarian cancer diagnosis and treatment
- Pleural and Pulmonary Diseases
- Biomarkers in Disease Mechanisms
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Ferroptosis and cancer prognosis
- Bone Metabolism and Diseases
- Urologic and reproductive health conditions
- Otolaryngology and Infectious Diseases
- Ureteral procedures and complications
- Cancer, Stress, Anesthesia, and Immune Response
- Prostate Cancer Treatment and Research
Huazhong University of Science and Technology
2022-2023
Sun Yat-sen University
2020-2022
Sun Yat-sen University Cancer Center
2020-2022
Southern Medical University
2020-2022
Union Hospital
2022
Meizhou City People's Hospital
2017
First Affiliated Hospital of Xinjiang Medical University
2014
Xinjiang Medical University
2014
Kunming Medical University
2014
Purpose Recurrent renal cell carcinoma(reRCC) is associated with poor prognosis and the underlying mechanism not yet clear. A comprehensive understanding of tumor microenvironment (TME) reRCC may aid in designing effective anticancer therapies, including immunotherapies. Single-cell transcriptomics holds great promise for investigating TME, however, this technique has been used reRCC. Here, we aimed to explore difference TME gene expression pattern between primary RCC (pRCC) at single-cell...
Abstract Clinically, patients with urothelial carcinoma of the bladder (UCB) tumor metastasis are incurable. To find new therapeutic strategies, mechanisms underlying UCB invasion and should be further investigated. In this study, zinc finger homeobox 3 (ZHX3) was first screened as a critical oncogenic factor associated poor prognosis in dataset from The Cancer Genome Atlas (TCGA). These results were also confirmed large cohort clinical samples. Next, we found that ZHX3 could promote...
RNA-binding proteins (RBPs) are key regulators of gene expression. RBP dysregulation is reported to play essential roles in tumorigenesis. However, the role RBPs urothelial carcinoma bladder (UCB) only starting be unveiled. Here, we comprehensively assessed mRNA expression landscape 104 from two independent UCB cohorts, Sun Yat-sen University Cancer Center (SYSUCC) and The Genome Atlas (TCGA). Fragile X-related 1 (FXR1) was identified as a novel cancer driver UCB. FXR1 overexpression found...
Obstructive pneumonitis, the opacity that develops distal to an obstructing endobronchial lesion or external compression, is actually a combination of atelectasis, bronchiectasis with mucus plugging, and true parenchymal inflammation. In majority cases, it usually not possible determine whether infection present from radiographic findings alone. The aim this study was evaluate bacteriology obstructive pneumonitis influence result on treatment patients. From March 1992 February 1993, 26...
Background: Increasing number of patients with metastatic renal cell carcinoma (mRCC) are receiving subsequent programmed death protein-1 (PD-1) inhibitor combination therapy following tyrosine-kinase (TKI) resistance. To explore whether PD-1 would further deteriorate proteinuria and function, we observed their proteinuria's function's condition since the administration inhibitor. Methods: assess change in data 141 mRCC treated TKI were collected, 66 whom prescribed Proteinuria estimated...
Radical/cytoreductive nephrectomy or nephron-sparing surgery may be thought to not safe unfeasible in some renal cell carcinoma (RCC) patients which tumor is locally advanced highly complicated. Neoadjuvant therapy reduce the volume of tumor, thus facilitates surgery. The aim study evaluate efficacy and safety neoadjuvant combination pazopanib axitinib PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) immunotherapy those patients.Data from 16 RCC who received (Group P, n=9)...
Abstract Sunitinib is one of the first‐line targeted drugs for metastatic renal cell carcinoma (RCC) with dual effects antiangiogensis and proapoptosis. Sam68 (Src‐associated in mitosis, 68 KDa), found being involved apoptosis. This article reveals that impacts sensitivity to sunitinib by mediating apoptosis RCC cells. Immunohistochemical staining indicated expression levels sensitive tumor tissues were markedly higher than those resistant tissues. induced a concentration‐dependent manner...
Abstract Multidrug resistance gene 1 (MDR1), a key factor contributing to drug insensitivity, has been associated with treatment failure and poor prognoses in various cancers, including bladder urothelial carcinoma (UC). Here we show that positive Nkx2.8 expression was better prognosis of UC patients received chemotherapy. Patients had promising from adjuvant Enforced promotes sensitivity cells. Mechanistic investigations showed negatively regulated MDR1 by binds directly the promoter...
14551 Background: Sunitinib is a multi-targeted tyrosine kinase inhibitor with proven efficacy against renal cell carcinoma (RCC). demonstrates immunomodulatory characteristics which may potentially augment the potency of tumor vaccines. We examined effect sunitinib therapy on measures cellular immunity and its ability to reverse associated immune suppression mediated by regulatory T cells (Tregs) inhibitory molecule PD-L1 (programmed death ligand-1). Methods: Peripheral blood was collected...
Few studies have focused on the performance of Briganti 2012, 2017 and MSKCC nomograms in Chinese population assessing risk lymph node invasion(LNI) prostate cancer(PCa) patients identifying suitable for extended pelvic dissection(ePLND). We aimed to develop validate a novel nomogram based PCa treated with radical prostatectomy(RP) ePLND predicting LNI.We retrospectively retrieved clinical data 631 localized receiving RP at single tertiary referral center. All had detailed biopsy information...
You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-18 NEOADJUVANT COMBINATION OF PAZOPANIB OR AXITINIB AND PD-1-ACTIVATED DC-CIK CELLS IMMUNOTHERAPY MAY FACILITATE SURGERY IN PATIENTS WITH RENAL CELL CARCINOMA Longbin Xiong, Zeshen Wu, Pei Dong, Huiming Liu, Kang Ning, Yulu Peng, Chunping Yu, Ya Ding, Desheng Weng, Jianchuan Xia, Lijuan Jiang, Shengjie Guo, Hui Han, Fangjian Zhou, and Zhiling Zhang XiongLongbin Xiong More articles by this...